The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise

Article metrics

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1

References

  1. 1

    UNAIDS & World Health Organization. AIDS Epidemic Update: November 2009. http://www.who.int/hiv/pub/tuapr_2009_en.pdf (UNAIDS, Geneva, 2009).

  2. 2

    World Health Organization, UNAIDS & UNICEF. Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector. http://www.who.int/hiv/pub/tuapr_2009_en.pdf (World Health Organization, Geneva, 2009).

  3. 3

    Virgin, H.W. & Walker, B.D. Nature 464, 224–231 (2010).

  4. 4

    Rerks-Ngarm, S. et al. N. Engl. J. Med. 361, 2209–2220 (2009).

  5. 5

    Haase, A.T. Nature 464, 217–223 (2010).

  6. 6

    McMichael, A.J., Borrow, P., Tomaras, G.D., Goonetilleke, N. & Haynes, B.F. Nat. Rev. Immunol. 10, 11–23 (2010).

  7. 7

    Keele, B.F. et al. Proc. Natl. Acad. Sci. USA 105, 7552–7557 (2008).

  8. 8

    Keele, B.F. & Derdeyn, C.A. Curr. Opin. HIV AIDS 4, 352–357 (2009).

  9. 9

    Fischer, W. et al. Nat. Med. 13, 100–106 (2007).

  10. 10

    Kosmrlj, A. et al. Nature 465, 350–354 (2010).

  11. 11

    Owen, R.E. et al. AIDS 24, 1095–1105 (2010).

  12. 12

    Hansen, S.G. et al. Nat. Med. 15, 293–299 (2009).

  13. 13

    Walker, L.M. et al. Science 326, 285–289 (2009).

  14. 14

    Wu, X. et al. Science 329, 856–861 (2010).

  15. 15

    Corti, D. et al. PLoS ONE 5, e8805 (2010).

  16. 16

    Hessell, A.J. et al. Nature 449, 101–104 (2007).

  17. 17

    Lambotte, O. et al. AIDS 23, 897–906 (2009).

  18. 18

    Xiao, P. et al. J. Virol. 84, 7161–7173 (2010).

  19. 19

    Centres, R. Lancet 370, 1665 (2007).

  20. 20

    Johnston, M.I. & Fauci, A.S. N. Engl. J. Med. 359, 888–890 (2008).

  21. 21

    Corey, L., McElrath, M.J. & Kublin, J.G. AIDS 23, 3–8 (2009).

  22. 22

    Klausner, R.D. et al. Science 300, 2036–2039 (2003).

  23. 23

    Coordinating Committee of the Global HIV/AIDS Vaccine Enterprise. PLoS Med. 2, e25 (2005).

  24. 24

    Montefiori, D. et al. PLoS Med. 4, e348 (2007).

  25. 25

    Shattock, R.J. et al. PLoS Med. 5, e81 (2008).

  26. 26

    Schief, W.R., Ban, Y.A. & Stamatatos, L. Curr. Opin. HIV AIDS 4, 431–440 (2009).

  27. 27

    UNAIDS & World Health Organization. Ethical Considerations in Biomedical HIV Prevention Trials: UNAIDS, WHO guidance document. http://data.unaids.org/pub/manual/2007/jc1349_ethics_2_11_07_en.pdf (UNAIDS, Geneva, 2007).

  28. 28

    UNAIDS & AVAC. Good Participatory Practice: Guidelines for Biomedical HIV Prevention Trials. (UNAIDS, Geneva, 2007).

  29. 29

    Mascola, J., King, R.C., Steinman, R. & the Working Group convened by the Global HIV Vaccine Enterprise. Preprint at http://precedings.nature.com/documents/4796/version/2 (2010).

  30. 30

    McMichael, A., McCutchan, F. & the Working Group convened by the Global HIV Vaccine Enterprise. Preprint at http://precedings.nature.com/documents/4797/version/2 (2010).

  31. 31

    Pulendran, B., Rappuoli, R., Aderem, A. & the Working Group convened by the Global HIV Vaccine Enterprise. Preprint at http://precedings.nature.com/documents/4798/version/2 (2010).

  32. 32

    Corey, L., Autran, B., Picker, L. & the Working Group convened by the Global HIV Vaccine Enterprise. Preprint at http://precedings.nature.com/documents/4799/version/2 (2010).

  33. 33

    Barouch, D.H. et al. Preprint at http://precedings.nature.com/documents/4800/version/2 (2010).

  34. 34

    Davis, M.M. Immunity 29, 835–838 (2008).

  35. 35

    Robinson, E.T. et al. Communications Handbook for Clinical Trials (Family Health International, Research Triangle Park, NC, 2010).

  36. 36

    Fellay, J. et al. PLoS Genet. 5, e1000791 (2009).

  37. 37

    Le Clerc, S. et al. J. Infect. Dis. 200, 1194–1201 (2009).

  38. 38

    Woodman, Z. & Williamson, C. Curr. Opin. HIV AIDS 4, 247–252 (2009).

  39. 39

    Querec, T.D. et al. Nat. Immunol. 10, 116–125 (2009).

  40. 40

    Geschwind, D.H. & Konopka, G. Nature 461, 908–915 (2009).

  41. 41

    Gaucher, D. et al. J. Exp. Med. 205, 3119–3131 (2008).

  42. 42

    Pulendran, B. Nat. Rev. Immunol. 9, 741–747 (2009).

  43. 43

    Committee on Science, Engineering, and Public Policy. Ensuring the Integrity, Accessibility, and Stewardship of Research Data in The Digital Age. (National Academies Press,Washington, DC, 2009).

  44. 44

    McDermott, A.B. et al. J. Virol. 78, 3140–3144 (2004).

  45. 45

    HIV Vaccines and Microbicides Resource Tracking Working Group. Advancing the Science in a Time of Fiscal Constraint: Funding for HIV Prevention Technologies in 2009. http://www.hivresourcetracking.org/downloads/RTWG%20Advancing%20the%20Science.final.pdf (2010).

  46. 46

    Bongaarts, J. & Over, M. Science 328, 1359–1360 (2010).

Download references

Acknowledgements

The 2010 Scientific Strategic Plan of the Global HIV Vaccine Enterprise was developed through a broad process of consultation. Thanks are given to the co-chairs of the various Enterprise Working Groups (A. Aderem, B. Autran, D. Barouch, L. Corey, R. King, J. Mascola, F. McCutchan, A. McMichael, T. Ndung'u, L. Picker, B. Pulendran, R. Rappuoli and R. Steinman), to Working Group members and to the Enterprise Science Committee for their invaluable insights and recommendations that have informed the development of this document. R. Lackman, R. Wiley and B. Snow provided much appreciated assistance and advice. Special thanks to A. Manrique and Y. Voronin for their invaluable support, input and suggestions at all stages during the process of developing the Plan.

Author information

Correspondence to Alan Bernstein.

Ethics declarations

Competing interests

The author declare no competing financial interests.

Additional information

Complete lists of authors and affiliations appear at the end of this paper.

Note: Opinions reflected in this manuscript do not necessarily reflect the official policies of the agencies represented by Council members.

Rights and permissions

Reprints and Permissions

About this article

Further reading